** California-based drugmaker Gilead Sciences GILD.O posted Q4 results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs
** Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday
A HEALTHY PROGNOSIS
** J.P.Morgan ("overweight," PT: $120) sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis $(PBC)$ in 2025, leading to optimism about co's future
** Mizuho ("outperform," PT: $100) sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes
** Piper Sandler ("overweight," PT: $110) sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones
** RBC Capital Markets ("sector perform," PT: $90) says they are cautious about complexities and costs associated with CAR-T for cancer treatment and ongoing launch of lena PrEP- a preventative HIV drug
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.